GlassScriptPhysician profile
Jean G Henry
NPI 1023174745
$6,792.98
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $978 · 2021: $1,744 · 2022: $1,226 · 2023: $23.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $833.55 | 2019-2022 | |
| Valeritas, INC. | $799.83 | 2019 | |
| Lilly USA, LLC | $505.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $494.03 | 2019-2022 | |
| Amgen INC. | $463.06 | 2019-2022 | |
| Abbott Laboratories | $424.05 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $334.30 | 2019-2022 | |
| Amarin Pharma, INC. | $259.70 | 2019-2021 | |
| Abbvie INC. | $243.27 | 2019-2023 | |
| Corcept Therapeutics | $225.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $219.16 | 2019-2022 | |
| Mannkind Corporation | $211.33 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $205.05 | 2019-2022 | |
| Insulet Corporation | $183.13 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.20 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $142.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Medtronic Minimed, INC. | $102.90 | 2019-2020 | |
| Zealand Pharma US, INC. | $91.17 | 2021-2022 | |
| Radius Health, INC. | $79.43 | 2019-2022 | |
| Acerus Pharmaceuticals Corporation | $65.67 | 2021 | |
| Becton, Dickinson and Company | $64.07 | 2019-2021 | |
| Aytu Biopharma, INC. | $50.81 | 2019-2020 | |
| Lifescan, INC. | $49.07 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $48.50 | 2019-2022 | |
| Cequr Corporation | $47.77 | 2022 | |
| Medtronic, INC. | $41.18 | 2021-2022 | |
| Eisai INC. | $40.65 | 2019 | |
| Amryt Pharma Holdings LTD | $37.50 | 2022 | |
| Tandem Diabetes Care, INC. | $37.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $36.01 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $35.58 | 2019-2020 | |
| Companion Medical, INC. | $31.17 | 2019-2020 | |
| Senseonics, Incorporated | $24.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.26 | 2020 | |
| Shire North American Group INC | $16.97 | 2019 | |
| Recordati_rare_diseases_inc. | $15.92 | 2020 | |
| Pfizer INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.